Today: 9 April 2026
Subscribe
Browse Category

NYSE:ABBV 10 January 2026 - 25 January 2026

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie shares closed up 0.99% at $216.15 Wednesday, trading near typical volume ahead of its Feb. 4 earnings report. Bernstein’s Courtney Breen maintained a Market Perform rating and $225 target. Investors are watching for 2026 guidance and updates on AbbVie’s new drug performance. Details of a recent pricing deal with the Trump administration remain undisclosed.
22 January 2026
·
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie shares rose about 0.5% to $221.89 in after-hours trading Wednesday after executives outlined plans to expand into obesity treatments. The company is betting on GUBamy, a drug licensed from Denmark’s Gubra, and highlighted its focus on amylin-based therapies. Investors are watching for pricing pressure from Washington ahead of AbbVie’s Feb. 4 earnings report.
15 January 2026
··
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
13 January 2026
··
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie shares fell 0.6% to $218.81 after announcing a $650 million licensing deal with China’s RemeGen for the experimental cancer drug RC148. RemeGen could receive up to $4.95 billion in milestones and royalties. AbbVie also agreed to buy a device manufacturing plant in Tempe, Arizona, from West Pharmaceutical Services. The S&P health-care sector declined while the broader market rose.
12 January 2026
···
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie shares fell 1.8% to $220.08 Friday after the company cut its Q4 and 2025 profit forecasts, citing a $1.3 billion charge for acquired R&D and milestone expenses. The company denied rumors of takeover talks with Revolution Medicines. AbbVie will present at the J.P. Morgan Healthcare Conference on Jan. 14 and report earnings on Feb. 4.
10 January 2026
···
1 2 3 4 5

Stock Market Today

  • Ares Management (ARES) Share Price Drops 37% YTD, Valuation Concerns Raised
    April 8, 2026, 8:05 PM EDT. Ares Management's (ARES) shares have fallen 37% year-to-date despite solid long-term gains, highlighting shifting investor sentiment in alternative asset managers. The stock trades around $104.83, but valuation models suggest a lower intrinsic value of $87.61, implying a 19.7% overvaluation. Metrics like book value ($12.68 per share) and earnings per share ($5.79) underpin this analysis. Ares' high return on equity (27.6%) contrasts with a cost of equity at $1.93, yet excess returns indicate value creation may not justify the current share price. Investors are advised to weigh fee-based revenue models against market risk reassessments. Simply Wall St rates ARES 0/6 on valuation checks, signaling caution amid volatile market conditions.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop